Acrivon Therapeutics, Inc. (ACRV) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.69

From 52W high−42.19%

Volume127758.00

Market cap$74.56M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.69

From 52W high

−42.19%

Volume

127758.00

Market cap

$74.56M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

44.4

MomentumView details →

1D Return

+4.19%

YTD Return

−29.05%

SummaryUpdated Jun 1, 2026

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Watertown, Massachusetts. The company went public in November 2022 and focuses on developing precision oncology medicines using its proprietary proteomics-based platform to identify patients most likely to respond to specific cancer treatments. Acrivon operates in the competitive biotechnology sector, specifically targeting DNA damage response pathways in cancer cells.

Ask drillr about Acrivon Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−85.65%

ROA (TTM)

−74.91%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+16.44%

FCF YoY

+12.37%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+3.81%

EBITDA YoY

+9.78%

MomentumView details →

1D Return

+4.19%

YTD Return

−29.05%

1Y Return

−15.76%

RSI (14)

44.4

vs 50D SMA

−10.31%

vs 200D SMA

−3.06%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

7.99x

Quick Ratio

7.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.43

EPS Surprise

14.38%

Beats (12Q)

8/12

Next Q EPS Est

−$0.43

Avg Surprise (4Q)

7.98%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−74.22M

Op. CF (TTM)

−62.92M

Next earningsNov 12, 2026 →

Latest newsMore news →

Acrivon Therapeutics, Inc. announced that early Phase 1/2 results for its ACR-2316 inhibitor will be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.7d ago

Similar companies

OKYO Pharma LimitedOKYO China Regenerative Medicine International Limited08158.HK Nutriband Inc.NTRB Coya Therapeutics, Inc.COYA MediciNova, Inc.MNOV Corbus Pharmaceuticals Holdings, Inc.CRBP Find similar companies →

Latest newsMore news →

Acrivon Therapeutics, Inc. announced that early Phase 1/2 results for its ACR-2316 inhibitor will be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.7d ago